Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

Hazel Gale, Jacqueline Chakravarthy, Jeff Chang, Jeffrey M. Drazen, Jeffrey S. Heier, Jeffrey Sparrow, Ursula Spaide, Ursula Wolf-Schnurrbusch, Yoshihiro Yonekura, Ziad Zaman, Ziad Zarif, Zhiqiang Zhang, Zhuo Zhang, Zhuo Zhang, Zhuo